Unitat de Recerca, Hospital Universitari de Tarragona Joan XXIII, Institut d'Investigació Sanitària Pere Virgili, Universitat Rovira i Virgili, 43007 Tarragona, Spain; CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Instituto de Salud Carlos III, 28014 Madrid, Spain.
Unitat de Recerca, Hospital Universitari de Tarragona Joan XXIII, Institut d'Investigació Sanitària Pere Virgili, Universitat Rovira i Virgili, 43007 Tarragona, Spain; CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Instituto de Salud Carlos III, 28014 Madrid, Spain.
Stem Cell Reports. 2017 Oct 10;9(4):1109-1123. doi: 10.1016/j.stemcr.2017.07.014. Epub 2017 Sep 28.
Crohn's disease (CD) is characterized by the expansion of mesenteric fat, also known as "creeping fat." We explored the plasticity and immune properties of adipose-derived stem cells (ASCs) in the context of CD as potential key players in the development of creeping fat. Mesenteric CD-derived ASCs presented a more proliferative, inflammatory, invasive, and phagocytic phenotype than equivalent cells from healthy donors, irrespective of the clinical stage. Remarkably, ASCs from the subcutaneous depot of patients with CD also showed an activated immune response that was associated with a reduction in their immunosuppressive properties. The invasive phenotype of mesenteric CD ASCs was governed by an inflammasome-mediated inflammatory state since blocking inflammasome signaling, mainly the secretion of interleukin-1β, reversed this characteristic. Thus, CD alters the biological functions of ASCs as adipocyte precursors, but also their immune properties. Selection of ASCs with the best immunomodulatory properties is advocated for the success of cell-based therapies.
克罗恩病(CD)的特征是肠系膜脂肪扩张,也称为“爬行脂肪”。我们研究了脂肪来源干细胞(ASCs)在 CD 背景下的可塑性和免疫特性,认为它们是爬行脂肪发展的潜在关键因素。与健康供体的相应细胞相比,无论临床阶段如何,源自 CD 患者肠系膜的 ASC 均表现出更具增殖性、炎症性、侵袭性和吞噬性的表型。值得注意的是,来自 CD 患者的皮下脂肪库的 ASC 也表现出激活的免疫反应,这与它们的免疫抑制特性降低有关。ASC 的侵袭表型受炎性小体介导的炎症状态调控,因为阻断炎性小体信号(主要是白细胞介素-1β的分泌)可逆转这一特征。因此,CD 改变了 ASC 作为脂肪细胞前体的生物学功能,但不改变其免疫特性。提倡选择具有最佳免疫调节特性的 ASC 以确保细胞治疗的成功。